{"id":"jr-141","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune responses/antibody formation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JR-141 uses a blood-brain barrier penetrating peptide technology to deliver functional arylsulfatase A enzyme into the central nervous system. This enzyme replacement therapy aims to restore enzymatic activity and reduce accumulation of sulfatide substrates in the brain and other tissues affected by arylsulfatase A deficiency. The drug is being developed for metachromatic leukodystrophy (MLD), a rare lysosomal storage disease.","oneSentence":"JR-141 is a recombinant human arylsulfatase A enzyme designed to cross the blood-brain barrier and replace deficient enzyme activity in lysosomal storage disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:41.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metachromatic leukodystrophy (MLD)"}]},"trialDetails":[{"nctId":"NCT04573023","phase":"PHASE3","title":"A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2022-02-14","conditions":"Mucopolysaccharidosis II","enrollment":86},{"nctId":"NCT05594992","phase":"PHASE3","title":"An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2023-02-22","conditions":"Mucopolysaccharidosis II","enrollment":80},{"nctId":"NCT03359213","phase":"PHASE2","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)","status":"COMPLETED","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2018-07-26","conditions":"Mucopolysaccharidosis II","enrollment":18},{"nctId":"NCT04348136","phase":"PHASE2, PHASE3","title":"An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II","status":"ACTIVE_NOT_RECRUITING","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2019-09-01","conditions":"Mucopolysaccharidosis II","enrollment":27},{"nctId":"NCT03708965","phase":"PHASE2","title":"An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II","status":"ACTIVE_NOT_RECRUITING","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2019-01-01","conditions":"Mucopolysaccharidosis II","enrollment":19},{"nctId":"NCT03568175","phase":"PHASE2, PHASE3","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis II","status":"COMPLETED","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2018-08-01","conditions":"Mucopolysaccharidosis II","enrollment":28},{"nctId":"NCT03128593","phase":"PHASE1, PHASE2","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis Type II","status":"COMPLETED","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2017-03-30","conditions":"Mucopolysaccharidosis II","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JR-141","genericName":"JR-141","companyName":"JCR Pharmaceuticals Co., Ltd.","companyId":"jcr-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JR-141 is a recombinant human arylsulfatase A enzyme designed to cross the blood-brain barrier and replace deficient enzyme activity in lysosomal storage disorders. Used for Metachromatic leukodystrophy (MLD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}